MultiplAI Health is developing ground-breaking RNA-based, AI-driven screening technology in the form of a simple blood test to transform how cardiovascular diseases are diagnosed.
Cardiovascular diseases are the leading cause of mortality globally, responsible for almost 18 million deaths per year.
Today, diagnostics are often inaccurate and time-consuming. General practitioners still rely on single biochemical markers such as cholesterol and blood pressure which can fail to recognise the signs of increased risk of suffering a major cardiovascular event. In turn, late diagnosis and inadequate prognosis decrease the chances for successful intervention with primary cardiovascular preventive measures, ultimately creating financial and psychological strain for the patient, their families and their doctors.
We want to change this by making routine and frequent screening for cardiovascular diseases possible for anyone on earth.
We offer a whole blood screening test using RNA Sequencing and Artificial Intelligence to detect complex diseases, including cardiovascular disorders and cancer.
Rather than searching for a single molecule that identifies a cardiovascular risk, our test identifies molecular variances in the blood that indicate an increased risk of a cardiovascular event. Imagine measuring all blood RNA changes that a cardiac risk factor may induce at the same time: A powerful, deep and accurate superbiomarker.
This gives MultiplAI the power to:
MultiplAI brings together maturing artificial intelligence algorithms, cost-effective sequencing and remote medicine to detect cardiovascular and other complex diseases and better establish prognosis based on the biological substrate.
It’s time to imagine modern universal remote screening for cardiovascular diseases.
With advances in RNA sequencing, bioinformatic processing and deep learning, we now have the power to measure many biomarkers in the blood.
Our patented RNAseq data transformation process makes it possible to represent the incredible complexity of RNA in highly efficient formats ideal for algorithmic analysis.
Molecular biologist and biotech
specialist with experience
co-founding a bioprinting startup
(WeBio). Investigator at
FLENI-CONICET with 20
Medical Doctor with 20+ years in
clinical cardiology. Director of a basic
and translational lab working on
cutting-edge cellular and molecular
biology. Data scientist and coder
looking to innovate in medicine.
Serial entrepreneur, angel investor
and advisor to startups with 25+
years of corporate finance and
open innovation experience.
Serial entrepreneur and
computer scientist with contacts
in Europe and Israel, and expertise
in data science, engineering and
Senior pharmaceutical executive
based in Boston with 20+ years of
experience in clinical oncology and
A serial entrepreneur and part-timeacademic based in Cambridge UK.He is the originator of the TripleChasm Approach, which challengescurrent dogma about how innovationsare commercialised.
For more information and presentation of our offering, please contact us.